The Ledger

Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.

clear all ✕

why aren't all 3 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable

Assertion Supported
GSK made AI core to its strategy via in-house functional genomics
“They're fully investing in the things I thought were very important at the time, which was, you know, these large genetic databases coming online and functional genomics. So he was way ahead in the, in sort of the thinking about CRISPR and like the gene pertur…”
Kim Branson Aug 1, 2024 ▶ 5:32 AI in Pharmaceutical R&D with Kim Branson
Assertion Partly supported
Hirasaki: Major biopharma companies faced critical patent cliffs in 2018
“Roche lost exclusivity on Zolaire and Rituxin. Pfizer lost exclusivity on Lyrica. And GSK lost exclusivity on Advair.”
Koki Hirasaki Feb 28, 2019 ▶ 1:30 What’s with All the Bio M&A in 2019?: A Quick Take
Assertion Partly supported
Branson notes Relenza was designed using early computational drug discovery methods
“So, so, I was working with Joseph Aghese and Peter Coleman and Brian Smith, and these are the people behind the first neuro-interdates drive, which actually was designed actually with computation. So, they used a program called Goodford This grid to map the pr…”
Kim Branson Aug 1, 2024 ▶ 1:54 AI in Pharmaceutical R&D with Kim Branson
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,000 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.